Compare KIDS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | ENTA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.2M | 374.6M |
| IPO Year | 2016 | 2012 |
| Metric | KIDS | ENTA |
|---|---|---|
| Price | $16.53 | $14.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $24.67 | $20.40 |
| AVG Volume (30 Days) | ★ 143.7K | 110.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | N/A | ★ N/A |
| Revenue | $98,049,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $14.07 | $7.76 |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.95 | 16.48 |
| 52 Week Low | $14.91 | $4.96 |
| 52 Week High | $23.70 | $17.15 |
| Indicator | KIDS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 57.22 |
| Support Level | $15.70 | $13.39 |
| Resistance Level | $19.15 | $15.52 |
| Average True Range (ATR) | 0.77 | 0.76 |
| MACD | 0.20 | 0.20 |
| Stochastic Oscillator | 47.73 | 74.84 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.